Supplement to “Dissecting Heterogeneity of Treatment Response of First-Episode Schizophrenia”: Response to Tobacco Warnings by Young Adults with First-Episode Schizophrenia
Principal Investigator: Anil Malhotra
Funding Mechanism: National Institutes of Health- Grant
ID Number: 3P50MH080173-05S2
Award Date: 8/15/2012
Institution: Feinstein Institute for Medical Research
Half of young adults with schizophrenia smoke. No research studies have assessed how young people with schizophrenia respond to tobacco warnings (which were designed for the general population), despite the likelihood that schizophrenia patients may respond differently to warning messages due to the effects of their condition (e.g., psychotic symptoms, cognitive deficits). The goal of this supplement is to provide data on the acceptability and efficacy of tobacco warnings for young people with and without schizophrenia . Specific aims are: (1) to compare young people with and without schizophrenia with regard to responses to tobacco warnings and perceptions of warning effectiveness; (2) to assess responses to, and effectiveness of, video tobacco warnings; and (3) to examine the impact of warnings on smoking knowledge, attitudes and behavior in both groups and the effects of symptoms and cognition on warning effectiveness among smokers with schizophrenia. To accomplish these aims, researchers will recruit 100 subjects with first-episode schizophrenia (50 smokers and 50 non-smokers) and 100 healthy subjects matched for age, sex and smoking status. Researchers will present subjects with text/picture and video warnings and, for each warning, will assess subjects’ perceptions of the warning’s effectiveness and subjective responses. One month later, researchers will assess subjects for retained knowledge and effects of the warnings. Study findings may inform the development of tobacco warnings that are effective for young people with and without schizophrenia.